The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Biomarker directed therapies in biliary tract cancers
Approximately 40% of biliary tract cancer harbor gene alterations that can be targeted with precision-based medicines. James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the targetable mutations in biliary tract cancer and the future of the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
